Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-06-19Clinical Trial Update: A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer [Phase 2]
This document reports a phase 2 clinical trial evaluating PCS6422 in combination with capecitabine for advanced or metastatic breast cancer,…
-
CLINICAL_TRIALS trial_result · 2025-06-17Clinical Trial Update: Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer [NA]
A completed Emory University study evaluating a mobile health intervention to improve adherence to oral chemotherapy in women with breast ca…
-
CLINICAL_TRIALS trial_result · 2025-06-13Clinical Trial Update: A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands [Phase 1]
Phase 1 clinical trial update of LGK974, a Wnt pathway inhibitor, in malignancies dependent on Wnt ligands; the study included several cance…
-
CLINICAL_TRIALS trial_result · 2025-06-13Clinical Trial Update: A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) [Phase 1, Phase 2]
AstraZeneca's Dato-DXd is being studied in a Phase 1/2 trial (TROPION-PanTumor02) in Chinese patients with advanced non-small cell lung canc…
-
CLINICAL_TRIALS research · 2025-06-13Clinical Trial Update: Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients [Phase 3]
Phase 3 clinical trial comparing UTD2 plus capecitabine to capecitabine alone as adjuvant therapy for patients with non-pCR triple-negative …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-06-12Clinical Trial Update: To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors [Phase 1, Phase 2]
This update covers a completed Phase 1/2 clinical trial evaluating Tinengotinib (TT-00420) as both monotherapy and in combination therapy fo…
-
CLINICAL_TRIALS research · 2025-06-12Clinical Trial Update: Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
Real-world clinical trial update on sacituzumab govitecan as monotherapy or in combination for recurrent or metastatic HER2-negative breast …
-
CLINICAL_TRIALS trial_result · 2025-06-11Clinical Trial Update: "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer [Phase 1, Phase 2]
Clinical trial update notes the termination of a Phase 1/2 trial evaluating atezolizumab plus RP1 oncolytic immunotherapy in the neoadjuvant…
-
CLINICAL_TRIALS trial_result · 2025-06-11Clinical Trial Update: AVID100 in Advanced Epithelial Carcinomas [Phase 1, Phase 2]
A phase 1/2 trial of AVID100 for advanced epithelial carcinomas was terminated; results were posted in June 2025.
-
CLINICAL_TRIALS research · 2025-06-11Clinical Trial Update: Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer [Phase 3]
Phase 3 trial evaluating safety and efficacy of an antibody linked to chemotherapy for triple-negative metastatic breast cancer; trial is cu…
-
CLINICAL_TRIALS research · 2025-06-10Clinical Trial Update: Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC [Phase 2]
This clinical trial update describes a Phase 2 study of pembrolizumab as immune-checkpoint blockade after partial breast irradiation in pati…
-
CLINICAL_TRIALS research · 2025-06-06Clinical Trial Update: Arsenous Acid for Refractory Triple-Negative Breast Cancer [Phase 2]
A Phase 2 clinical trial is investigating arsenous acid for refractory triple-negative breast cancer and is currently recruiting.
-
CLINICAL_TRIALS research · 2025-06-05Clinical Trial Update: Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO [Phase 3]
A Phase 3 trial is evaluating whether an immune-oncology therapy given every three months after six months of standard administration is as …
-
CLINICAL_TRIALS research · 2025-06-05Clinical Trial Update: Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer [Phase 2]
A Phase 2 clinical trial is evaluating QL1706 in combination with olaparib for previously treated homologous recombination repair-deficient …
-
CLINICAL_TRIALS trial_result · 2025-06-04Clinical Trial Update: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies [Phase 1]
A Phase Ib safety study of Selinexor (KPT-330) in combination with standard chemotherapy or immunotherapy agents for patients with advanced …
-
CLINICAL_TRIALS trial_result · 2025-05-31Clinical Trial Update: Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer [Phase 2]
A Phase 2 trial evaluating a circulating tumor DNA–enriched, genomically directed post-neoadjuvant approach for patients with residual tripl…
-
CLINICAL_TRIALS research · 2025-05-31Clinical Trial Update: Exercise in Triple- Negative Breast Cancer [NA]
The document indicates a clinical trial investigating exercise in Triple-negative breast cancer is currently recruiting at Technical Univers…
-
CLINICAL_TRIALS research · 2025-05-28Clinical Trial Update: Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration
A study is evaluating first-line therapy with Sacituzumab Govitecan plus Toripalimab for advanced triple-negative breast cancer, with biomar…
-
CLINICAL_TRIALS trial_result · 2025-05-28Clinical Trial Update: Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy [Phase 2]
Phase 2 clinical trial evaluating circulating tumor DNA-guided boost therapy for early triple-negative breast cancer patients with residual …
-
CLINICAL_TRIALS trial_result · 2025-05-23Clinical Trial Update: A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors [Phase 1, Phase 2]
A clinical trial update reports termination of the NM21-1480 study in adults with advanced solid tumors, including non-small cell lung cance…
-
CLINICAL_TRIALS research · 2025-05-23Clinical Trial Update: Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer [EARLY_Phase 1]
An early-phase adjuvant trial of an alpha-lactalbumin vaccine in triple-negative breast cancer (Stage IIA-IIIC) is currently active but not …
-
CLINICAL_TRIALS research · 2025-05-22Clinical Trial Update: Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors [Phase 1]
This ClinicalTrials.gov update describes a Phase 1 study evaluating MNPR-101-DFO*-89Zr as a diagnostic imaging agent for adults with various…
-
CLINICAL_TRIALS research · 2025-05-22Clinical Trial Update: Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC) [NA]
A clinical trial evaluating bemotuzumab in combination with neoadjuvant chemotherapy for triple-negative breast cancer; the study status is …
-
CLINICAL_TRIALS research · 2025-05-21Clinical Trial Update: A Study of Pembrolizumab and Cryoablation in People With Breast Cancer [Phase 1]
Phase 1 clinical trial evaluating pembrolizumab in combination with cryoablation for various breast cancers; currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-05-21Clinical Trial Update: Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors [Phase 1]
Phase 1 dose-escalation study of MNPR-101-PCTA-177Lu in solid tumors is currently recruiting across multiple cancer indications.